The increase in adiponectin expression and plasma levels with drugs already existing or with novel therapeutic strategies is therefore considered valuable in the prevention and treatment of obesity-related metabolic and cardiovascular diseases in humans. This evidence concerns the gene ADIPOQ and cardiovascular disorder.